Non-optimal Treatment in Early line Patients With Chronic Myeloid Leukemia in ChronicPhase (CML-CP) Treated with Tyrosine Kinase Inhibitors (TKI): A Claims Data Analysis
07:30am - 03:35pm EDT - April 6, 2024


Non-optimal Treatment in Early line Patients With Chronic Myeloid Leukemia in ChronicPhase (CML-CP) Treated with Tyrosine Kinase Inhibitors (TKI): A Claims Data Analysis icon

Abstract: JNCCN23-0644 https://jnccn.org/view/journal...


Author(s):
  • David Wei, PhD, Director, US HEOR Hematology, Novartis Pharmaceuticals Corporation

Tags: Outcomes and Health Services Research

Display Label Action
Kota et al. NCCN 24 Poster_Final_2_29_2024.pdf Download Handout